The National Prescribing Centre’s NPCi (UK) posted at their blog an analysis on the results of the ACCOMPLISH study. Here, an excerpt:

The ACCOMPLISH study suggests that in patients at high risk of CV disease, and who require dual antihypertensive therapy to control blood pressure, a combination of an ACE inhibitor (benazepril) and a calcium channel blocker (amlodipine) may be more effective than a combination of benazepril with a thiazide diuretic (hydrochlorothiazide).

The MeReC (UK) recommends that:

Prescribers should not change practice on the basis of this one clinical study and should continue to follow the NICE clinical guideline for the management of hypertension until such time as the evidence can be considered in the context other studies, and guidelines modified, if appropriate

Dual antihypertensive therapy in patients at high risk of CV disease (ACCOMPLISH study). NPCi blog